Combination of (i) a human anti-FGFR4 antibody or a functional fragment of said antibody and (ii) Sorafenib or a pharmaceutically acceptable salt thereof, for use in the prevention and/ or treatment of a hyperproliferative disease associated with FGFR4 expression, overexpression and/or hyperactivity, wherein the hyperproliferative disease is cancer, wherein the human anti-FGFR4 antibody or the functional fragment of said antibody is directed against an epitope between amino acids 119-248, preferably between amino acids 152-240, more preferably between amino acids 230 and 240 of human FGFR4 and wherein the human anti-FGFR4 antibody or the functional fragment of said antibody comprises (i) a heavy chain comprising: a heavy chain complementarity determining region 1 (CDRH1) having the sequence as shown in SEQ ID No.: 3, a heavy chain complementarity determining region 2 (CDRH2) having the sequence as shown in SEQ ID No.: 8, and a heavy chain complementarity determining region 3 (CDRH3) having the sequence as shown in SEQ ID No.: 15, and (ii) a light chain comprising: a light chain complementarity determining region 1 (CDRL1) having the sequence as shown in SEQ ID No.: 23, a light chain complementarity determining region 2 (CDRL2) having the sequence as shown in SEQ ID No.: 25, and a light chain complementarity determining region 3 (CDRL3) having the sequence as shown in SEQ ID No.: 30. wherein the human anti-FGFR4 antibody or the functional fragment of said antibody is directed against an epitope between amino acids 119-248, preferably between amino acids 152-240, more preferably between amino acids 230 and 240 of human FGFR4 and wherein the human anti-FGFR4 antibody or the functional fragment of said antibody comprises (i) a heavy chain comprising: a heavy chain complementarity determining region 1 (CDRH1) having the sequence as shown in SEQ ID No.: 3, a heavy chain complementarity determining region 2 (CDRH2) having the sequence as shown in SEQ ID No.: 8, and a heavy chain complementarity determining region 3 (CDRH3) having the sequence as shown in SEQ ID No.: 15, and (ii) a light chain comprising: a light chain complementarity determining region 1 (CDRL1) having the sequence as shown in SEQ ID No.: 23, a light chain complementarity determining region 2 (CDRL2) having the sequence as shown in SEQ ID No.: 25, and a light chain complementarity determining region 3 (CDRL3) having the sequence as shown in SEQ ID No.: 30. (i) a heavy chain comprising: a heavy chain complementarity determining region 1 (CDRH1) having the sequence as shown in SEQ ID No.: 3, a heavy chain complementarity determining region 2 (CDRH2) having the sequence as shown in SEQ ID No.: 8, and a heavy chain complementarity determining region 3 (CDRH3) having the sequence as shown in SEQ ID No.: 15, and (ii) a light chain comprising: a light chain complementarity determining region 1 (CDRL1) having the sequence as shown in SEQ ID No.: 23, a light chain complementarity determining region 2 (CDRL2) having the sequence as shown in SEQ ID No.: 25, and a light chain complementarity determining region 3 (CDRL3) having the sequence as shown in SEQ ID No.: 30. a light chain complementarity determining region 1 (CDRL1) having the sequence as shown in SEQ ID No.: 23, a light chain complementarity determining region 2 (CDRL2) having the sequence as shown in SEQ ID No.: 25, and a light chain complementarity determining region 3 (CDRL3) having the sequence as shown in SEQ ID No.: 30.